Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 158.10
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 4 2 24 5 1 6 5 3 — — —
Insider Ownership 0.32%

Capital & Financial Ratios $m

Market Cap 128,950.00
Revenue 12,587.20
Net Income 4,405.20
Free Cash Flow 3,796.10
Net Debt (7,852.40)
Current Ratio 3.19 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 28.82
Fwd P/E 25.50
P/S ratio 10.07 (above 10: high)
P/B ratio 6.26 (above 6: high)
Past 5Y EPS Growth 8.29%
This Y EPS Growth 1.52%
Next Y EPS Growth 12.69%
Next Y revenue growth 10.45% (at or above 10%: strong)
Next 5Y EPS Growth 10.99%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.5×, against a ten-year median of 10.7×; over the ten years it ranged from 5.7× in 2021 to 20.9× in 2016.
P/E against its own 10 years 57.09%
10-year low 10-year high
P/S against its own 10 years 38.52%
10-year low 10-year high
P/B against its own 10 years 31.29%
10-year low 10-year high
EV/Sales against its own 10 years 39.11%
10-year low 10-year high
EV/FCF against its own 10 years 54.53%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 11,218 6,116 6,608 7,852
Receivables 1,563 1,609 2,053 2,134
Inventory 739 1,205 1,687 1,765
Other — — — —
14,144 9,596 11,201 12,544
2023 2024 2025 Q'26
Payables 365 413 462 430
ST’ Debt — — — —
Other 527 363 428 329
3,547 3,565 3,861 3,938

Compound Annual Growth %

10y 5y 3y
Sales 27.80% 14.10% 10.35%
Cash Flow 0.00% 2.22% (4.20%)
Earnings 0.00% 7.83% 5.97%
Book Value 32.81% 16.53% 10.29%

Revenue $m

Mar Jun Sep Dec Year
’26 2,987 3,334 — — —
’25 2,770 2,965 3,076 3,190 12,001
’24 2,691 2,646 2,772 2,912 11,020
’23 2,375 2,493 2,484 2,518 9,869
’22 2,098 2,196 2,334 2,303 8,931
’21 1,724 1,793 1,984 2,073 7,574
’20 1,515 1,524 1,538 1,628 6,206
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1,428 1,125 — — —
’25 819 1,073 1,241 498 3,631
’24 1,307 (3,754) 1,370 585 (493)
’23 900 1,134 1,268 235 3,537
’22 956 1,140 956 1,078 4,130
’21 921 (200) 927 995 2,644
’20 816 1,039 908 492 3,254
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1,295 1,013 — — —
’25 778 927 1,140 349 3,194
’24 1,058 (3,830) 1,302 492 (978)
’23 858 1,075 1,228 119 3,279
’22 893 1,087 901 1,045 3,925
’21 850 (250) 875 933 2,409
’20 796 1,021 733 444 2,994
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 4.02 4.31 — — —
’25 2.49 3.99 4.20 4.65 15.32
’24 4.21 (13.92) 4.01 3.50 (2.08)
’23 2.69 3.52 3.97 3.71 13.89
’22 2.96 3.13 3.59 3.15 12.82
’21 2.49 0.26 3.28 3.00 9.01
’20 2.29 3.18 2.53 2.30 10.29
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 71.46 73.34 144.07 160.95 197.47 176.36 214.66 282.21 377.85 362.50

Analyst estimates 2026–2028

Powerpack
High 124.96 167.86 194.92 225.66 306.08 242.99 324.75 413.00 519.88 519.68
People
People Employees 2,150 2,300 2,500 3,000 3,400 3,900 4,800 5,400 6,100 6,400
Revenue/emp, $m 0.79 1.08 1.22 1.39 1.83 1.94 1.86 1.83 1.81 1.88
Income, $m
Income, $m Revenue 1,702 2,489 3,048 4,163 6,206 7,574 8,931 9,869 11,020 12,001
Gross margin, % 87.64 88.95 86.56 86.84 88.14 88.06 87.90 87.21 86.11 86.24
EBT (67) (16) 600 1,395 3,117 2,730 4,232 4,380 249 4,643
EBT margin, % (3.96) (0.63) 19.70 33.51 50.23 36.05 47.39 44.38 2.25 38.69
Net income (84) 92 2,087 1,177 2,712 2,342 3,322 3,620 (536) 3,953
Depreciation 61 61 72 107 110 126 148 181 207 210
Per share, $
Per share, $ Revenue 6.96 10.00 11.98 16.22 23.89 29.39 34.87 38.30 42.73 46.94
Earnings (0.46) 1.06 8.24 4.58 10.44 9.09 12.97 14.05 (2.08) 15.46
Cash flow 0.96 3.40 5.00 6.11 12.52 10.26 16.13 13.73 (1.91) 14.20
Capex (0.23) (0.40) (0.38) (0.29) (1.00) (0.91) (0.80) (1.00) (1.88) (1.71)
Free cash flow 0.73 3.00 4.62 5.82 11.52 9.35 15.33 12.72 (3.79) 12.49
Book value 5.47 8.21 17.44 23.71 33.44 39.19 54.33 68.22 63.63 73.00
Shares, m 245 249 254 257 260 258 256 258 258 256
Valuation, ×
Valuation, × P/E 0.00 142.91 20.11 47.91 22.68 24.13 22.04 29.27 0.00 29.31
P/S 10.77 15.29 13.83 13.50 9.89 7.47 8.20 10.73 9.42 9.66
P/B 13.69 18.63 9.50 9.24 7.07 5.60 5.27 6.02 6.33 6.21
EV/Sales 10.38 14.81 13.08 12.79 8.96 6.58 7.08 9.66 8.91 9.14
EV/FCF 98.38 49.43 33.92 35.63 18.57 20.71 16.10 28.57 (100.36) 34.36
Cash, $m
Cash, $m Operating cash flow 236 845 1,270 1,569 3,254 2,644 4,130 3,537 (493) 3,631
Capex (57) (99) (95) (75) (260) (235) (205) (258) (485) (438)
Free cash flow 180 746 1,175 1,494 2,994 2,409 3,925 3,279 (978) 3,194
Balance, $m
Balance, $m Working capital 1,039 1,842 2,723 3,488 6,256 7,419 10,493 10,597 6,032 7,340
Total debt 821 584 582 539 539 510 431 376 113 —
Net debt (661) (1,505) (2,587) (3,270) (6,120) (7,015) (10,348) (10,842) (6,003) (6,608)
Shareholders’ equity 1,338 2,042 4,435 6,085 8,687 10,100 13,913 17,580 16,410 18,666
Returns, %
Returns, % ROA (4.15) 8.18 42.83 16.16 27.02 18.60 21.04 17.71 (2.37) 16.41
ROIC 0.92 14.33 21.48 26.58 69.55 56.37 75.52 35.54 (1.40) 21.63
ROE (9.22) 15.59 64.74 22.37 36.71 24.93 27.67 22.99 (3.15) 22.54
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Vertex Pharmaceuticals Incorporated vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VRTX Vertex Pharmaceuticals Incorporated $129.0B 28.8× 25.5× +12.45% (above 0%: growing) +7.96% (above 0%: growing) +9.25% (above 0%: growing) 85.33% 37.40%
MRNA Moderna, Inc. $94.4B — (loss-making) — (loss-making) +2.11% (above 0%: growing) n/m +38.94% (above 0%: growing) 35.86% (562.07%) Compare
REGN Regeneron Pharmaceuticals, Inc. $82.0B 18.9× 16.5× +16.73% (above 0%: growing) −4.68% (below 0%: shrinking) −29.26% (below 0%: shrinking) 86.56% 30.15% Compare
ARGX argenex SE $53.2B 29.6× 32.4× +59.46% (above 0%: growing) +88.56% (above 0%: growing) +537.51% (above 0%: growing) 90.60% 32.04% Compare
RVMD Revolution Medicines, Inc. $40.6B — (loss-making) — (loss-making) −77.89% (below 0%: shrinking) n/m −69.98% (below 0%: shrinking) 100.00% 0.00% Compare
ONC BeOne Medicines Ltd. - Sponsored ADR $39.0B 62.6× 40.2× +29.63% (above 0%: growing) +143.68% (above 0%: growing) +117.92% (above 0%: growing) 89.76% 19.06% Compare
RPRX Royalty Pharma PLC $34.3B 42.3× 21.9× +16.50% (above 0%: growing) −40.00% (below 0%: shrinking) +31.57% (above 0%: growing) 100.00% 19.75% Compare
ALNY Alnylam Pharmaceuticals, Inc. $31.3B 39.5× 39.6× +66.86% (above 0%: growing) n/m +152.82% (above 0%: growing) 76.88% 17.93% Compare
ROIV Roivant Sciences Ltd. $24.6B — (loss-making) — (loss-making) −33.55% (below 0%: shrinking) n/m −29.99% (below 0%: shrinking) 80.31% (25,380.93%) Compare
Median of peers $39.8B 39.5× 32.4× +16.62% +41.94% +35.26% 88.16% 18.50%

All 614 Biotechnology stocks →

VRTX metrics, ten years each

Vertex Pharmaceuticals Incorporated (VRTX) key facts

  • Strength: Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
  • Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • Net income was $4.0 billion, or $15.46 per share (basic), a net margin of 32.9%.
  • As of October 16, 2026, VRTX traded at $499.39, a market capitalization of $129.0 billion.
  • At that price the stock trades at 28.8× trailing-twelve-month earnings and 10.1× sales; its P/E is higher than 57% of its own readings over the past ten years.
  • Return on equity was 22.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 12.06 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Vertex Pharmaceuticals Incorporated (VRTX) Latest News

10 Jul

Impact 5 ·

7 Jul

Impact 5 ·
Impact 5 ·

1 Apr

Impact 5 ·

10 Mar

Impact 5 ·

9 Mar

Impact 5 ·

24 Jun

Impact 5 ·

21 Jun

Impact 5 ·
stockrow.com/VRTX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com